Noveris Health SciencesMYCOF 23 Current Ratio is 0.48 as of Mar. 2026, which is 6% below its 10-year median of 0.51. GuruFocus rates MYCOF with a GF Score™ of 23/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 996 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 93.88% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Noveris Health Sciences's current ratio for the quarter that ended in Mar. 2026 was 0.48.
Noveris Health Sciences has a current ratio of 0.48. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Noveris Health Sciences has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Noveris Health Sciences's Current Ratio or its related term are showing as below:
MYCOF'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.51 Max: 5.97
Current: 0.48
During the past 13 years, Noveris Health Sciences's highest Current Ratio was 5.97. The lowest was 0.01. And the median was 0.51.
MYCOF's Current Ratio is ranked worse than 93.88% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs MYCOF: 0.48
Noveris Health Sciences (OTCPK:MYCOF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Noveris Health Sciences Current Ratio Related Terms
Noveris Health Sciences Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a Current Ratio of 0.48 as of Mar. 2026. This is near median its historical median of 0.51. Over the past decade, Noveris Health Sciences' Current Ratio has ranged from 0.01 to 5.97. According to the industry distribution chart, Noveris Health Sciences ranks #935 out of 996 companies in the Drug Manufacturers industry, placing it in the top 93.9%.
Is Noveris Health Sciences' Current Ratio too high?
Noveris Health Sciences' current Current Ratio of 0.48 is near median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 5.97. The Drug Manufacturers industry median Current Ratio is 2.00. Noveris Health Sciences' value of 0.48 is 76% below this industry median. Based on the distribution chart, Noveris Health Sciences ranks #935 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #935 out of 996 companies for Current Ratio. This places Noveris Health Sciences in the lower half of its industry. The industry median Current Ratio is 2.00. Noveris Health Sciences' value of 0.48 is 76% below this benchmark. Historically, Noveris Health Sciences' own Current Ratio has ranged from 0.01 to 5.97 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 2.00, Noveris Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noveris Health Sciences's current Current Ratio of 0.48 is 76% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Current Ratio is 0.48, which is near median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $2.00 — trading 284.6% above its estimated fair value. The current Current Ratio is 0.48, which is near median its 10-year median of 0.51 and 76% below the Drug Manufacturers industry median of 2.00. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Current Ratio is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noveris Health Sciences (MYCOF) Overvalued in 2026?
Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued.
The current stock price of $2.00 is trading 284.6% above its estimated GF Value™ of $0.52.
GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.
Key valuation signals for MYCOF:
Current Ratio: 0.48 (near median its 10-year median of 0.51)
GF Value™: $0.52 vs. price of $2.00 (284.6% above fair value)
Industry Position: 76% below the Drug Manufacturers median (#935 of 996)
No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
